<!DOCTYPE html>
<html lang="en" dir="ltr" prefix="og: https://ogp.me/ns#">
  <head>
    <meta charset="utf-8" />
<meta property="og:site_name" content="Vertex Pharmaceuticals" />
<meta property="og:type" content="website" />
<meta property="og:url" content="https://investors.vrtx.com/press-releases" />
<meta property="og:title" content="Press Releases | Vertex Pharmaceuticals" />
<meta property="og:description" content="The Investor Relations website contains information about Vertex Pharmaceuticals&#039;s business for stockholders, potential investors, and financial analysts." />
<meta name="Generator" content="Drupal 10 (https://www.drupal.org)" />
<meta name="MobileOptimized" content="width" />
<meta name="HandheldFriendly" content="true" />
<meta name="viewport" content="width=device-width, initial-scale=1.0" />
<link rel="icon" href="/sites/g/files/knoqqb74911/files/favicon.ico" type="image/vnd.microsoft.icon" />
<link rel="alternate" hreflang="en" href="https://investors.vrtx.com/press-releases" />
<link rel="canonical" href="https://investors.vrtx.com/press-releases" />
<link rel="shortlink" href="https://investors.vrtx.com/node/5816" />

    <title>Press Releases | Vertex Pharmaceuticals</title>
    <link rel="stylesheet" media="all" href="/sites/g/files/knoqqb74911/files/css/css_1HvT-90as-e3CXVWo_1w4S2XTy309NZf7XoB6NbSpLQ.css?delta=0&amp;language=en&amp;theme=nir_pid2172&amp;include=eJyVjUEKwzAMBD9kYppLnyNkW6QishRkJ6W_r5NboJdelmUYdpUdKvpKHQp2hCSW11gJFZyy1Uo6OJtCfqH3oD99VJRP6-BD1QUS-h96g45JKGRzisX3DWUqjGJLaMOiGhM2uqbOEs_C2bTdUTeTcXzBjcv8eM7RDnLnQuFgerd45VSt7EJfT5phrw" />
<link rel="stylesheet" media="all" href="/sites/g/files/knoqqb74911/files/css/css_Irk1fXP27BWbV6Mh5txGirKi1dfzWYXgLu8LcVhc-H0.css?delta=1&amp;language=en&amp;theme=nir_pid2172&amp;include=eJyVjUEKwzAMBD9kYppLnyNkW6QishRkJ6W_r5NboJdelmUYdpUdKvpKHQp2hCSW11gJFZyy1Uo6OJtCfqH3oD99VJRP6-BD1QUS-h96g45JKGRzisX3DWUqjGJLaMOiGhM2uqbOEs_C2bTdUTeTcXzBjcv8eM7RDnLnQuFgerd45VSt7EJfT5phrw" />
<link rel="stylesheet" media="all" href="//fonts.googleapis.com/css?family=Arimo:400,400italic,700,300italic" />
<link rel="stylesheet" media="all" href="//fonts.googleapis.com/css?family=Poiret+One" />
<link rel="stylesheet" media="all" href="//fonts.googleapis.com/css?family=Josefin+Slab:400,700,600,300" />
<link rel="stylesheet" media="all" href="/sites/g/files/knoqqb74911/files/css/css_WF_WjdFnydexFLH-q6EV4RnXpbWPAYGc92V0TcW0t5g.css?delta=5&amp;language=en&amp;theme=nir_pid2172&amp;include=eJyVjUEKwzAMBD9kYppLnyNkW6QishRkJ6W_r5NboJdelmUYdpUdKvpKHQp2hCSW11gJFZyy1Uo6OJtCfqH3oD99VJRP6-BD1QUS-h96g45JKGRzisX3DWUqjGJLaMOiGhM2uqbOEs_C2bTdUTeTcXzBjcv8eM7RDnLnQuFgerd45VSt7EJfT5phrw" />
<link rel="stylesheet" media="print" href="/sites/g/files/knoqqb74911/files/css/css_BafFCdsxiUI1wldlRvpIN5iLHxcBJGqNdV_v3x4wwU4.css?delta=6&amp;language=en&amp;theme=nir_pid2172&amp;include=eJyVjUEKwzAMBD9kYppLnyNkW6QishRkJ6W_r5NboJdelmUYdpUdKvpKHQp2hCSW11gJFZyy1Uo6OJtCfqH3oD99VJRP6-BD1QUS-h96g45JKGRzisX3DWUqjGJLaMOiGhM2uqbOEs_C2bTdUTeTcXzBjcv8eM7RDnLnQuFgerd45VSt7EJfT5phrw" />
<link rel="stylesheet" media="all" href="/sites/g/files/knoqqb74911/files/css/css_rnf9BGrG97ZF8sypxyVluZjd7arGQ8x7Upxx8ceBe3g.css?delta=7&amp;language=en&amp;theme=nir_pid2172&amp;include=eJyVjUEKwzAMBD9kYppLnyNkW6QishRkJ6W_r5NboJdelmUYdpUdKvpKHQp2hCSW11gJFZyy1Uo6OJtCfqH3oD99VJRP6-BD1QUS-h96g45JKGRzisX3DWUqjGJLaMOiGhM2uqbOEs_C2bTdUTeTcXzBjcv8eM7RDnLnQuFgerd45VSt7EJfT5phrw" />

    <script src="/core/assets/vendor/modernizr/modernizr.min.js?v=3.11.7"></script>
<script src="/sites/g/files/knoqqb74911/files/js/js_zcZJg2ceexb8o86eQ2I6FQDMa0-CSF5vKxCHlcH4HzE.js?scope=header&amp;delta=1&amp;language=en&amp;theme=nir_pid2172&amp;include=eJyVj0sOwjAMRC-EEtENB-AEiANETmIV0zSuEpfP7UldJATqBmXh8ctY9mQqLgwYSbi4CNKeT1jtR-5ys4xzEhqbDex3q78eKioX5uShKJwodvtDZ_mGpVBEhXf0lQRdZqHQ1mww867qr8JhcOECRexPb1QfF3mWZ6Lcr5dCGVA0ivOpOewmNYHHEXL8a0Y3nmaWNcwE_Rp7EQau8HAQowsJanWQsEh9AVtyirg"></script>

    <!-- OneTrust Cookies Consent Notice start for vrtx.com -->
<script src="https://cdn.cookielaw.org/scripttemplates/otSDKStub.js" data-document-language="true" type="text/javascript" charset="UTF-8" data-domain-script="55293c39-90c9-481e-be5a-a536e7236802" ></script>
<script type="text/javascript">
function OptanonWrapper() {
    var countryCode = OneTrust.getGeolocationData().country
    dataLayer.push({event:"GACountry", OneTrustCountryCode: countryCode})
}
</script>
<!-- OneTrust Cookies Consent Notice end for vrtx.com -->

<!-- Google Analytics Code -->
<script type="text/plain" class="optanon-category-C0002">
  (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){(i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
    m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)})
  (window,document,'script','//www.google-analytics.com/analytics.js','ga');
                                
  ga('create', 'UA-709045-2', 'auto');
  ga('send', 'pageview');
</script>

<!-- Google tag (gtag.js) -->
<script async src="https://www.googletagmanager.com/gtag/js?id=G-60HPP96Z4B" type="text/plain" class="optanon-category-C0002"></script>
<script type="text/plain" class="optanon-category-C0002"> window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-60HPP96Z4B'); </script> 


<!-- IrwinIQ Tag Manager --> <script> (function(w,d){ var _mtm = w._mtm = w._mtm || []; _mtm.push({'mtm.startTime': (new Date().getTime()), 'event': 'mtm.Start'}); var g=d.createElement('script'), s=d.getElementsByTagName('script')[0]; g.async=true; g.src='https://analytics.imirwin.com/js/container_rVlDBFll.js'; s.parentNode.insertBefore(g,s); })(window, document); </script> <!-- End IrwinIQ Tag Manager -->
  </head>
  <body class="body-sidebars-first nir-node nir-node--type-nir-landing-page nir-node--5816 path-node page-node-type-nir-landing-page">
    <div id="skip">
      <a class="visually-hidden focusable skip-link" href="#main-menu">
        Skip to main navigation
      </a>
    </div>
    
      <div class="dialog-off-canvas-main-canvas" data-off-canvas-main-canvas>
    

<a href="#skip-to-content" class="hide-txt">Skip to Content</a>

<div class="off-canvas-wrapper">

    <div class="off-canvas-wrapper-inner" data-off-canvas-wrapper>

        <div class="off-canvas position-left reveal-for-large" id="my-info" data-off-canvas data-position="left">
            <div class="row column">
                <span class="logo">
                  <br>
                  <a href="//www.vrtx.com/">
                  <!-- animated logo -->
                   <img class="logo-light" src="/sites/g/files/knoqqb74911/themes/site/nir_pid2172/client/images/white-vector.svg" alt="Vertex Pharmaceuticals">
                                        </a>
                  <br/>
                </span>

                <!-- nav -->
                <div class="row side-nav">
                    <div class="medium-8 medium-centered columns">
                        
    

<nav role="navigation" aria-labelledby="block-investorrelations-2-menu" class="block--system-menu-blockir block--system-menu-blockir--5816 block--sidebar-first--system-menu-block--ir block--sidebar-first--system-menu-block--ir--5816 block--e99e7083-5a42-4093-bf00-e1b8438402d1 block--e99e7083-5a42-4093-bf00-e1b8438402d1--5816 block block-menu navigation block-system-menublock menu--ir">
                        
    <h2 class="visually-hidden" id="block-investorrelations-2-menu">Investor Relations</h2>
    

                                            <ul data-block-uuid="e99e7083-5a42-4093-bf00-e1b8438402d1" class="vertical accordion-menu menu" data-accordion-menu>
                                        <li>
                <a href="/" target="" rel="" title="Main Investor Relations Page" data-drupal-link-system-path="&lt;front&gt;">Investors Home</a>
                            </li>
                                <li class="active-trail">
                <a href="/press-releases" target="" rel="" data-drupal-link-system-path="node/5816" class="is-active" aria-current="page">News &amp; Events</a>
                                                                <ul class="menu vertical">
                                        <li>
                <a href="/press-releases" data-drupal-link-system-path="node/5816" class="is-active" aria-current="page">Press Releases</a>
                            </li>
                                <li>
                <a href="/events-presentations" target="" rel="" data-drupal-link-system-path="node/24456">Events &amp; Presentations</a>
                            </li>
                </ul>
    
                            </li>
                                <li>
                <a href="/stock-information" data-drupal-link-system-path="node/5916">Stock Information</a>
                                                                <ul class="menu vertical">
                                        <li>
                <a href="/stock-information" target="" rel="" data-drupal-link-system-path="node/5916">Quote &amp; Chart</a>
                            </li>
                                <li>
                <a href="/stock-information/historic-stock-lookup" data-drupal-link-system-path="node/5921">Historic Stock Lookup</a>
                            </li>
                                <li>
                <a href="/stock-information/investment-calculator" data-drupal-link-system-path="node/5926">Investment Calculator</a>
                            </li>
                </ul>
    
                            </li>
                                <li>
                <a href="/stock-information/analyst-coverage" data-drupal-link-system-path="node/5896">Analyst Coverage</a>
                            </li>
                                <li>
                <a href="/financial-information/quarterly-results" target="" rel="" data-drupal-link-system-path="node/5986">Financial Information</a>
                                                                <ul class="menu vertical">
                                        <li>
                <a href="/financial-information/quarterly-results" data-drupal-link-system-path="node/5986">Quarterly Results</a>
                            </li>
                                <li>
                <a href="/financial-information/sec-filings" data-drupal-link-system-path="node/5876">SEC Filings</a>
                            </li>
                </ul>
    
                            </li>
                                <li>
                <a href="/corporate-governances" target="" rel="" data-drupal-link-system-path="node/24511">Corporate Governance</a>
                                                                <ul class="menu vertical">
                                        <li>
                <a href="http://www.vrtx.com/our-company/leadership">Leadership</a>
                            </li>
                                <li>
                <a href="http://www.vrtx.com/our-company/leadership/#board-of-directors">Board of Directors</a>
                            </li>
                                <li>
                <a href="/corporate-governances" target="" rel="" data-drupal-link-system-path="node/24511">Governance Documents</a>
                            </li>
                </ul>
    
                            </li>
                                <li>
                <a href="/contact-us" target="" rel="" data-drupal-link-system-path="node/5981">Investor Resources</a>
                                                                <ul class="menu vertical">
                                        <li>
                <a href="/contact-us" target="" rel="" data-drupal-link-system-path="node/5981">IR Contacts</a>
                            </li>
                                <li>
                <a href="/investor-faqs" target="" rel="" data-drupal-link-system-path="node/5941">FAQs</a>
                            </li>
                                <li>
                <a href="http://www.vrtx.com/medicines/our-approved-medicines">Approved Medicines</a>
                            </li>
                                <li>
                <a href="http://www.vrtx.com/our-science/pipeline">Pipeline</a>
                            </li>
                                <li>
                <a href="/email-alerts" data-drupal-link-system-path="node/5946">Email Alerts</a>
                            </li>
                </ul>
    
                            </li>
                </ul>
    


    </nav>
<div id="block-stockquote-2" data-storage-id="node:31451:flexible_layout" class="block--market-data-block__stock-quote block--market-data-block__stock-quote--31451 block--sidebar-first--market-data-block__stock-quote block--sidebar-first--market-data-block__stock-quote--31451 block--b23b16fc-7147-4bf3-bd29-2d329f8920d5 block--b23b16fc-7147-4bf3-bd29-2d329f8920d5--31451 block block-nir-market-data-block block-market-data-block__stock-quote">
  
    
      <div class='text-center'>
    <div class="quote-wrapper">
        <h5 class="text-center"></h5>
        <table class="stock-qupte">
            <tbody>
                                                                                                                                            <tr>
                    <td>Price</td>
                    <td></td>
                </tr>
                <tr>
                    <td>Change</td>
                    <td></td>
                </tr>
                                                </tbody>
        </table>
    </div>
</div>
<div class="stock-time">
     - </div>
  </div>

<div id="block-stockinfoattributionthomsonreuters" class="block--attribution-block__stock-info-attribution__thomson-reuters block--attribution-block__stock-info-attribution__thomson-reuters--31451 block--sidebar-first--attribution-block__stock-info-attribution__thomson-reuters block--sidebar-first--attribution-block__stock-info-attribution__thomson-reuters--31451 block--34dc1e1a-9db4-405e-8e35-49f1041b8bfc block--34dc1e1a-9db4-405e-8e35-49f1041b8bfc--31451 block block-nir-attribution-block block-attribution-block__stock-info-attribution__thomson-reuters">
  
    
      <p>
  Data Provided by Refinitiv. Delayed ~15m.</p>

  </div>

<div id="block-widgetstockchart" class="block--nir-stock-chart block--nir-stock-chart--31451 block--sidebar-first--nir-stock-chart block--sidebar-first--nir-stock-chart--31451 block--c72aa970-06ea-4045-b1b5-f20d0b0ba4f7 block--c72aa970-06ea-4045-b1b5-f20d0b0ba4f7--31451 block block-nir-stock-chart">
  
      <h2  id="block-nir-stock-chart">Nasdaq: VRTX</h2>
    
      
<img src="https://api.nasdaqomx.wallst.com/api/chart?display=mountain&symbol=VRTX.O-VRTX&scale=linear&duration=1yr&frequency=1dy&gridLine=n&bgColor=52247f&lineColor=ffffff&fillcolor=52247f|52247f&width=560&height=300&&amp;volume=0&amp;fontColor-C0=FFFFFF&amp;fontColor-C1=FFFFFF" width="560" height="300" ></img>

  </div>

                    </div>
                </div>

            </div>


                        <div class="stock text-center">
                  <div class="region region-sidebar-featured">
    <div id="block-shareholdertools-2" class="block--system-menu-blockshareholder-tools block--system-menu-blockshareholder-tools--31451 block--sidebar-featured--system-menu-block--shareholder-tools block--sidebar-featured--system-menu-block--shareholder-tools--31451 block--4121c46a-4fb3-40cf-a26e-3dc466a9248c block--4121c46a-4fb3-40cf-a26e-3dc466a9248c--31451 block block-system block-system-menu-blockshareholder-tools gcs-sidebar-block">
  
    
                    <ul data-block-uuid="4121c46a-4fb3-40cf-a26e-3dc466a9248c" class="tools">
          
                                              
        <li class="side-menu__item">
                    <a href="/email-alerts" title="Email Alerts" class="glyph-icon flaticon-alarm-1" target="">
            <span class="fa-stack">
            
                               <img src="/sites/g/files/knoqqb74911/themes/site/nir_pid2172/client/images/notifications.svg" alt="">
                
            </span>
          </a>

                  </li>
      
                                              
        <li class="side-menu__item">
                    <a href="/rss-news-feeds" title="RSS News Feeds" class="glyph-icon flaticon-newspaper" target="">
            <span class="fa-stack">
            
                              <img src="/sites/g/files/knoqqb74911/themes/site/nir_pid2172/client/images/rss_feed.svg" alt="">

              
            </span>
          </a>

                  </li>
      
                                                
        <li class="side-menu__item">
                    <a href="/investor-feedback" title="Investor Feedback" class="glyph-icon flaticon-paper-plane" target="">
            <span class="fa-stack">
            
                              <img src="/sites/g/files/knoqqb74911/themes/site/nir_pid2172/client/images/email.svg" alt="">
              
            </span>
          </a>

                  </li>
          </ul>
  


  </div>

  </div>

            </div>
            




        </div> <!-- /off-canvas -->

        <div class="off-canvas-content"  id="skip-to-content" data-off-canvas-content>

            <div class="title-bar hide-for-large">
                <div class="title-bar-left">
                    <button class="menu-icon" type="button" data-open="my-info" aria-label="Menu button"></button>
                    <span class="title-bar-title"><!-- Menu --></span>
                </div>
                <span class="logo">
                  <a href="//www.vrtx.com/">
                    <!-- static logo -->
                    <img class="logo-light" src="/sites/g/files/knoqqb74911/themes/site/nir_pid2172/client/images/white-vector.svg" alt="Vertex Pharmaceuticals">
                                        </a>
                </span>
            </div>

            <div class="callout primary">
                <div class="row">
                    <h1 class="header-title">

                                            News & Events
                                        </h1>

                                    </div>
            </div>

            

            


                            <div id="ndq-content" class="row ndq-5816 inside-pages large-12 columns">
                    <h2 class="h2content-heading">

                                                    Press Releases
                                            </h2>



                      <div class="region region-content">
    <div id="block-nir-pid2172-websitenoticeblock" class="block--website-notice-block block--website-notice-block--5816 block--content--website-notice-block block--content--website-notice-block--5816 block--dd8b7d55-3418-4333-8560-aa0535832f20 block--dd8b7d55-3418-4333-8560-aa0535832f20--5816 block block-nir-website-notices block-website-notice-block">
  
    
      
  </div>
<div data-drupal-messages-fallback class="hidden"></div>

<div id="block-nir-pid2172-content" class="block--system-main-block block--system-main-block--5816 block--content--system-main-block block--content--system-main-block--5816 block--32fb46b7-e82f-437f-b00f-4734f5697096 block--32fb46b7-e82f-437f-b00f-4734f5697096--5816 block block-system block-system-main-block">
  
    
      <article class="node node--type-nir_landing_page node--view-mode-full clearfix">
  
      <h1>
              Press Releases
          </h1>
    

  <div>
    
<div class="panel-display boxton clearfix " >

  <div class="container-fluid">
    <div class="row">
      <div class="columns large-12 radix-layouts-content panel-panel">
        <div class="panel-panel-inner">
          <div class="block-region-contentmain">
<div class="block--search-form block--search-form--5816 block--contentmain--search-form block--contentmain--search-form--5816 block--69c1a507-53a5-47e3-8700-d9cecb7ecae7 block--69c1a507-53a5-47e3-8700-d9cecb7ecae7--5816 block block-nir-search block-search-form">
  
    
      <form data-block-uuid="69c1a507-53a5-47e3-8700-d9cecb7ecae7" action="/search" method="get" accept-charset="UTF-8">
  <div class="js-form-item form-item js-form-type-search form-item-query js-form-item-query form-no-label">
        <input type="search" name="query" size="60" maxlength="128" placeholder="What are you looking for today?" class="form-search required" required="required" aria-required="true" />

        </div>
<input type="hidden" name="f[0]" value="type:nir_news" />
<input type="submit" name="op" value="Search" class="button button--primary js-form-submit form-submit" />

</form>

  </div>

<div class="views-element-container block--views-blockwidget-news-table block--views-blockwidget-news-table--5816 block--contentmain--views-block--widget-news-table block--contentmain--views-block--widget-news-table--5816 block--c9e9f210-6659-4313-bbd1-f20963e32837 block--c9e9f210-6659-4313-bbd1-f20963e32837--5816 block block-views block-views-blockwidget-news-table">
  
    
      <div data-block-uuid="c9e9f210-6659-4313-bbd1-f20963e32837"><div class="view view-widget-news view-id-widget_news view-display-id-table js-view-dom-id-2d48cfcdc609e62d908bdd3f4e3df33a30aa0c4fd470401746615906c917281e">
  
    
      
      <div class="view-content">
      <table class="nirtable views-table views-view-table cols-3 collapse-table">
        <thead>
      <tr>
                                                  <th id="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date" scope="col"><a href="?order=field_nir_news_date&amp;sort=asc" title="sort by Date">Date</a></th>
                                                  <th id="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title" scope="col"><a href="?order=field_nir_news_title&amp;sort=asc" title="sort by Title and Summary">Title and Summary</a></th>
                                                  <th id="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format" scope="col">Additional Formats</th>
              </tr>
    </thead>
    <tbody>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2025-03-07T15:02:00Z" timezone="America/New_York" class="datetime">Mar 7, 2025</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-announces-uk-mhra-approval-alyftrekr" hreflang="en">Vertex Announces UK MHRA Approval of ALYFTREK® (Deutivacaftor/Tezacaftor/Vanzacaftor), a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  - Deutivacaftor/tezacaftor/vanzacaftor approved for people with cystic fibrosis 6 years and older with at least one responsive mutation in the CFTR gene, including additional mutations not previously approved with other CFTR modulator therapies - - In head-to-head clinical trials,
  </summary>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-announces-uk-mhra-approval-alyftrekr" target="_self">View HTML</a></span>
<div class="file-link pdf-file-link">
  <span class="file file--mime-application-pdf file--application-pdf"><a href="/node/33176/pdf" type="application/pdf" target="_blank">PDF Version</a></span>
</div>          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2025-02-28T12:22:00Z" timezone="America/New_York" class="datetime">Feb 28, 2025</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-receives-chmp-positive-opinion-expanded-label-kaftrior" hreflang="en">Vertex Receives CHMP Positive Opinion for Expanded Label for KAFTRIO® in Combination With Ivacaftor for People With Cystic Fibrosis to Include Rare Mutations</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  -If approved, approximately 4,000 people with cystic fibrosis in the European Union will be eligible for a medicine that treats the underlying cause of their disease for the first time- LONDON --(BUSINESS WIRE)--Feb. 28, 2025-- Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European
  </summary>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-receives-chmp-positive-opinion-expanded-label-kaftrior" target="_self">View HTML</a></span>
<div class="file-link pdf-file-link">
  <span class="file file--mime-application-pdf file--application-pdf"><a href="/node/33106/pdf" type="application/pdf" target="_blank">PDF Version</a></span>
</div>          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2025-02-18T21:05:00Z" timezone="America/New_York" class="datetime">Feb 18, 2025</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-participate-upcoming-march-investor-conferences" hreflang="en">Vertex to Participate in Upcoming March Investor Conferences</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  BOSTON --(BUSINESS WIRE)--Feb. 18, 2025-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced management participation in three upcoming investor conferences. Stuart Arbuckle , Executive Vice President and Chief Operating Officer, and David Altshuler , M.D., Ph.D., Executive Vice
  </summary>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-participate-upcoming-march-investor-conferences" target="_self">View HTML</a></span>
<div class="file-link pdf-file-link">
  <span class="file file--mime-application-pdf file--application-pdf"><a href="/node/32951/pdf" type="application/pdf" target="_blank">PDF Version</a></span>
</div>          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2025-02-10T21:01:00Z" timezone="America/New_York" class="datetime">Feb 10, 2025</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-reports-fourth-quarter-and-full-year-2024-financial" hreflang="en">Vertex Reports Fourth Quarter and Full Year 2024 Financial Results</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  — Full year product revenue of $11.02 billion , a 12% increase compared to full year 2023 — — Company provides full year 2025 total revenue guidance of $11.75 to $12.0 billion — — ALYFTREK™ approved in the U.S. for patients ages 6+ with cystic fibrosis; JOURNAVX™ approved in the U.S.
  </summary>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-reports-fourth-quarter-and-full-year-2024-financial" target="_self">View HTML</a></span>
<div class="file-link pdf-file-link">
  <span class="file file--mime-application-pdf file--application-pdf"><a href="/node/32781/pdf" type="application/pdf" target="_blank">PDF Version</a></span>
</div>          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2025-01-31T07:00:00Z" timezone="America/New_York" class="datetime">Jan 31, 2025</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-announces-casgevyr-reimbursement-agreement-treatment" hreflang="en">Vertex Announces CASGEVY® Reimbursement Agreement for the Treatment of Sickle Cell Disease in England</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  - Agreement means eligible sickle cell disease (SCD) patients in England now have access to CASGEVY - - Agreement for CASGEVY in transfusion-dependent beta thalassemia (TDT) was previously reached in August 2024 - LONDON --(BUSINESS WIRE)--Jan. 31, 2025-- Vertex Pharmaceuticals (Nasdaq: VRTX)
  </summary>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-announces-casgevyr-reimbursement-agreement-treatment" target="_self">View HTML</a></span>
<div class="file-link pdf-file-link">
  <span class="file file--mime-application-pdf file--application-pdf"><a href="/node/32721/pdf" type="application/pdf" target="_blank">PDF Version</a></span>
</div>          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2025-01-30T23:25:00Z" timezone="America/New_York" class="datetime">Jan 30, 2025</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-announces-fda-approval-journavxtm-suzetrigine-first-class" hreflang="en">Vertex Announces FDA Approval of JOURNAVX™ (suzetrigine), a First-in-Class Treatment for Adults With Moderate-to-Severe Acute Pain</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  &lt;p&gt;-- JOURNAVX is the first and only approved non-opioid oral pain signal inhibitor and the first new class of pain medicine approved in more than 20 years -- -- JOURNAVX is an effective and well-tolerated medicine without evidence of addictive potential indicated for use across all types of&lt;/p&gt;
  </summary>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-announces-fda-approval-journavxtm-suzetrigine-first-class" target="_self">View HTML</a></span>
<div class="file-link pdf-file-link">
  <span class="file file--mime-application-pdf file--application-pdf"><a href="/node/32716/pdf" type="application/pdf" target="_blank">PDF Version</a></span>
</div>          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2025-01-27T12:30:00Z" timezone="America/New_York" class="datetime">Jan 27, 2025</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-announce-fourth-quarter-and-full-year-2024-financial" hreflang="en">Vertex to Announce Fourth Quarter and Full Year 2024 Financial Results on February 10</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  BOSTON --(BUSINESS WIRE)--Jan. 27, 2025-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its fourth quarter and full year 2024 financial results on Monday, February 10, 2025 after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET .
  </summary>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-announce-fourth-quarter-and-full-year-2024-financial" target="_self">View HTML</a></span>
<div class="file-link pdf-file-link">
  <span class="file file--mime-application-pdf file--application-pdf"><a href="/node/32711/pdf" type="application/pdf" target="_blank">PDF Version</a></span>
</div>          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2025-01-12T22:01:00Z" timezone="America/New_York" class="datetime">Jan 12, 2025</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-provides-pipeline-and-business-updates-advance-upcoming-0" hreflang="en">Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  BOSTON --(BUSINESS WIRE)--Jan. 12, 2025-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced multiple program updates ahead of upcoming investor meetings in January, including the company’s scheduled webcast from the 43 rd Annual J.P. Morgan Healthcare Conference on Monday, January
  </summary>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-provides-pipeline-and-business-updates-advance-upcoming-0" target="_self">View HTML</a></span>
<div class="file-link pdf-file-link">
  <span class="file file--mime-application-pdf file--application-pdf"><a href="/node/32691/pdf" type="application/pdf" target="_blank">PDF Version</a></span>
</div>          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2025-01-10T12:30:00Z" timezone="America/New_York" class="datetime">Jan 10, 2025</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-and-zai-lab-announce-strategic-agreement-develop-and" hreflang="en">Vertex and Zai Lab Announce Strategic Agreement to Develop and Commercialize Povetacicept in Mainland China, Hong Kong SAR, Macau SAR, Taiwan Region and Singapore</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  - Exclusive collaboration and licensing agreement for povetacicept in the region - - Zai Lab will leverage its local expertise and commercial footprint to accelerate development of povetacicept and bring the medicine to eligible patients in the region if approved - BOSTON &amp;amp; SHANGHAI &amp;amp; CAMBRIDGE,
  </summary>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-and-zai-lab-announce-strategic-agreement-develop-and" target="_self">View HTML</a></span>
<div class="file-link pdf-file-link">
  <span class="file file--mime-application-pdf file--application-pdf"><a href="/node/32681/pdf" type="application/pdf" target="_blank">PDF Version</a></span>
</div>          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2024-12-23T21:05:00Z" timezone="America/New_York" class="datetime">Dec 23, 2024</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-present-43rd-annual-jp-morgan-healthcare-conference" hreflang="en">Vertex to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  BOSTON --(BUSINESS WIRE)--Dec. 23, 2024-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Dr. Reshma Kewalramani , Chief Executive Officer and President, will present at the 43 rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 10:30 a.m.
  </summary>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-present-43rd-annual-jp-morgan-healthcare-conference" target="_self">View HTML</a></span>
<div class="file-link pdf-file-link">
  <span class="file file--mime-application-pdf file--application-pdf"><a href="/node/32666/pdf" type="application/pdf" target="_blank">PDF Version</a></span>
</div>          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2024-12-20T20:46:00Z" timezone="America/New_York" class="datetime">Dec 20, 2024</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-announces-us-fda-approval-alyftrektm-once-daily-next" hreflang="en">Vertex Announces US FDA Approval of ALYFTREK™, a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  - ALYFTREK ™ is approved for patients 6 years and older with at least one responsive mutation, including 31 additional mutations not responsive to other CFTR modulator therapies - - In head-to-head clinical trials, ALYFTREK was non-inferior on ppFEV 1 and further decreased sweat chloride compared
  </summary>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-announces-us-fda-approval-alyftrektm-once-daily-next" target="_self">View HTML</a></span>
<div class="file-link pdf-file-link">
  <span class="file file--mime-application-pdf file--application-pdf"><a href="/node/32656/pdf" type="application/pdf" target="_blank">PDF Version</a></span>
</div>          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2024-12-20T20:35:00Z" timezone="America/New_York" class="datetime">Dec 20, 2024</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-announces-us-fda-approval-trikafta" hreflang="en">Vertex Announces U.S. FDA Approval for TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor) to Include Additional Non-F508del TRIKAFTA-Responsive Variants</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  - Approximately 300 more people with cystic fibrosis in the U.S. are now eligible for a medicine that treats the underlying cause of their disease for the first time - BOSTON --(BUSINESS WIRE)--Dec. 20, 2024-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S.
  </summary>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-announces-us-fda-approval-trikafta" target="_self">View HTML</a></span>
<div class="file-link pdf-file-link">
  <span class="file file--mime-application-pdf file--application-pdf"><a href="/node/32651/pdf" type="application/pdf" target="_blank">PDF Version</a></span>
</div>          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2024-12-19T11:00:00Z" timezone="America/New_York" class="datetime">Dec 19, 2024</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-announces-results-phase-2-study-suzetrigine-treatment" hreflang="en">Vertex Announces Results From Phase 2 Study of Suzetrigine for the Treatment of Painful Lumbosacral Radiculopathy</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  – Treatment with the highly selective NaV1.8 pain signal inhibitor suzetrigine met the primary endpoint with a statistically significant and clinically meaningful 2.02 point within-group reduction from baseline in the Numeric Pain Rating Scale (NPRS) – – Placebo arm showed similar within-group
  </summary>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-announces-results-phase-2-study-suzetrigine-treatment" target="_self">View HTML</a></span>
<div class="file-link pdf-file-link">
  <span class="file file--mime-application-pdf file--application-pdf"><a href="/node/32641/pdf" type="application/pdf" target="_blank">PDF Version</a></span>
</div>          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2024-12-08T17:52:00Z" timezone="America/New_York" class="datetime">Dec 8, 2024</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-presents-positive-long-term-data-casgevytm-0" hreflang="en">Vertex Presents Positive Long-Term Data On CASGEVY™ (exagamglogene autotemcel) at the American Society of Hematology (ASH) Annual Meeting and Exposition and Provides Program Update</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  - Data from long-term follow-up of patients in clinical trials further demonstrate durability of the transformative benefits of CASGEVY™ - - Safety profile consistent with busulfan conditioning and &amp;nbsp; autologous hematopoietic stem cell transplant - - Vertex provides update on progress in bringing
  </summary>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-presents-positive-long-term-data-casgevytm-0" target="_self">View HTML</a></span>
<div class="file-link pdf-file-link">
  <span class="file file--mime-application-pdf file--application-pdf"><a href="/node/32626/pdf" type="application/pdf" target="_blank">PDF Version</a></span>
</div>          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2024-11-04T21:01:00Z" timezone="America/New_York" class="datetime">Nov 4, 2024</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-reports-third-quarter-2024-financial-results" hreflang="en">Vertex Reports Third Quarter 2024 Financial Results</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  — Product revenue of $2.77 billion , a 12% increase compared to Q3 2023 — — Raising full-year product revenue guidance to $10.8 billion to $10.9 billion — — Preparing for two potential near-term launches: vanzacaftor triple in CF and suzetrigine (VX-548) for moderate-to-severe acute pain — —
  </summary>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-reports-third-quarter-2024-financial-results" target="_self">View HTML</a></span>
<div class="file-link pdf-file-link">
  <span class="file file--mime-application-pdf file--application-pdf"><a href="/node/32576/pdf" type="application/pdf" target="_blank">PDF Version</a></span>
</div>          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2024-10-29T20:05:00Z" timezone="America/New_York" class="datetime">Oct 29, 2024</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-participate-upcoming-november-investor-conferences" hreflang="en">Vertex to Participate in Upcoming November Investor Conferences</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  BOSTON --(BUSINESS WIRE)--Oct. 29, 2024-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced management participation in two upcoming investor conferences. Dr. Reshma Kewalramani , Chief Executive Officer and President, will participate in a fireside chat at the Guggenheim Inaugural
  </summary>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-participate-upcoming-november-investor-conferences" target="_self">View HTML</a></span>
<div class="file-link pdf-file-link">
  <span class="file file--mime-application-pdf file--application-pdf"><a href="/node/32561/pdf" type="application/pdf" target="_blank">PDF Version</a></span>
</div>          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2024-10-25T17:00:00Z" timezone="America/New_York" class="datetime">Oct 25, 2024</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-provides-updates-multiple-kidney-programs-american" hreflang="en">Vertex Provides Updates on Multiple Kidney Programs at the American Society of Nephrology (ASN) Annual Kidney Week Congress</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  - New data on povetacicept 80 mg SC Q4 weeks in IgA nephropathy shows mean UPCR reduction from baseline of 66% observed at 48 weeks, associated with stable renal function (eGFR) and 63% achieving clinical remission -- - First proteinuria data on povetacicept in primary membranous nephropathy shows
  </summary>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-provides-updates-multiple-kidney-programs-american" target="_self">View HTML</a></span>
<div class="file-link pdf-file-link">
  <span class="file file--mime-application-pdf file--application-pdf"><a href="/node/32546/pdf" type="application/pdf" target="_blank">PDF Version</a></span>
</div>          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2024-10-18T12:00:00Z" timezone="America/New_York" class="datetime">Oct 18, 2024</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-present-phase-3-data-highlighting-suzetrigines-potential" hreflang="en">Vertex to Present Phase 3 Data Highlighting Suzetrigine’s Potential as a First-in-Class, Highly Selective Pain Signal Inhibitor at the American Society of Anesthesiologists Annual Meeting</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  -- Phase 3 abstract selected for presentation in “Best Abstract” session -- BOSTON --(BUSINESS WIRE)--Oct. 18, 2024-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the company will present its pivotal Phase 3 data on suzetrigine, an investigational, oral, highly selective
  </summary>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-present-phase-3-data-highlighting-suzetrigines-potential" target="_self">View HTML</a></span>
<div class="file-link pdf-file-link">
  <span class="file file--mime-application-pdf file--application-pdf"><a href="/node/32536/pdf" type="application/pdf" target="_blank">PDF Version</a></span>
</div>          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2024-10-10T20:05:00Z" timezone="America/New_York" class="datetime">Oct 10, 2024</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-announce-third-quarter-2024-financial-results-november" hreflang="en">Vertex to Announce Third Quarter 2024 Financial Results on November 4th</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  BOSTON --(BUSINESS WIRE)--Oct. 10, 2024-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its third quarter 2024 financial results on Monday, November 4, 2024 after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET .
  </summary>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-announce-third-quarter-2024-financial-results-november" target="_self">View HTML</a></span>
<div class="file-link pdf-file-link">
  <span class="file file--mime-application-pdf file--application-pdf"><a href="/node/32521/pdf" type="application/pdf" target="_blank">PDF Version</a></span>
</div>          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2024-09-26T11:07:00Z" timezone="America/New_York" class="datetime">Sep 26, 2024</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-highlights-first-oral-presentation-phase-3-clinical-data" hreflang="en">Vertex Highlights First Oral Presentation of Phase 3 Clinical Data of the Vanza Triple and New Data on Long-Term Impact of TRIKAFTA® at the North American Cystic Fibrosis Conference</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  – &amp;nbsp; Phase 3 data on investigational vanza triple demonstrates non-inferiority to TRIKAFTA ® in ppFEV 1 and further improvement of CFTR function as measured by sweat chloride – – &amp;nbsp; Real-world evidence and clinical studies of TRIKAFTA ® continue to show sustained long-term benefits including
  </summary>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-highlights-first-oral-presentation-phase-3-clinical-data" target="_self">View HTML</a></span>
<div class="file-link pdf-file-link">
  <span class="file file--mime-application-pdf file--application-pdf"><a href="/node/32501/pdf" type="application/pdf" target="_blank">PDF Version</a></span>
</div>          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2024-08-22T12:00:00Z" timezone="America/New_York" class="datetime">Aug 22, 2024</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-participate-upcoming-september-investor-conferences" hreflang="en">Vertex to Participate in Upcoming September Investor Conferences</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  BOSTON --(BUSINESS WIRE)--Aug. 22, 2024-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced management participation in two upcoming investor conferences. Dr. Reshma Kewalramani , Chief Executive Officer and President, and Charles Wagner , Executive Vice President and Chief
  </summary>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-participate-upcoming-september-investor-conferences" target="_self">View HTML</a></span>
<div class="file-link pdf-file-link">
  <span class="file file--mime-application-pdf file--application-pdf"><a href="/node/32476/pdf" type="application/pdf" target="_blank">PDF Version</a></span>
</div>          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2024-08-07T23:12:00Z" timezone="America/New_York" class="datetime">Aug 7, 2024</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-announces-casgevytm-reimbursement-agreement-treatment" hreflang="en">Vertex Announces CASGEVY™ Reimbursement Agreement for the Treatment of Transfusion-Dependent Beta Thalassemia in England</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  - Eligible transfusion-dependent beta thalassemia (TDT) patients in England will be able to access the therapy from today - - CASGEVY is one of the first medicines funded by NHS England’s Innovative Medicines Fund - LONDON --(BUSINESS WIRE)--Aug. 7, 2024-- Vertex Pharmaceuticals (Nasdaq: VRTX)
  </summary>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-announces-casgevytm-reimbursement-agreement-treatment" target="_self">View HTML</a></span>
<div class="file-link pdf-file-link">
  <span class="file file--mime-application-pdf file--application-pdf"><a href="/node/32441/pdf" type="application/pdf" target="_blank">PDF Version</a></span>
</div>          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2024-08-01T20:01:00Z" timezone="America/New_York" class="datetime">Aug 1, 2024</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-reports-second-quarter-2024-financial-results" hreflang="en">Vertex Reports Second Quarter 2024 Financial Results</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  — Product revenue of $2.65 billion , a 6% increase compared to Q2 2023 — — Company raises full year product revenue guidance to $10.65 to $10.85 billion — — FDA accepted NDA for vanzacaftor triple in CF with Priority Review and PDUFA target action date of January 2, 2025 ; additionally, MAA
  </summary>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-reports-second-quarter-2024-financial-results" target="_self">View HTML</a></span>
<div class="file-link pdf-file-link">
  <span class="file file--mime-application-pdf file--application-pdf"><a href="/node/32401/pdf" type="application/pdf" target="_blank">PDF Version</a></span>
</div>          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2024-07-30T17:10:00Z" timezone="America/New_York" class="datetime">Jul 30, 2024</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-announces-fda-acceptance-new-drug-application-suzetrigine" hreflang="en">Vertex Announces FDA Acceptance of New Drug Application for Suzetrigine for the Treatment of Moderate-to-Severe Acute Pain</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  – FDA grants priority review and assigns a Prescription Drug User Fee Act (PDUFA) target action date of January 30, 2025 – – Suzetrigine, an investigational non-opioid pain signal inhibitor, has the potential to treat millions of patients who suffer from moderate-to-severe acute pain each year –
  </summary>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-announces-fda-acceptance-new-drug-application-suzetrigine" target="_self">View HTML</a></span>
<div class="file-link pdf-file-link">
  <span class="file file--mime-application-pdf file--application-pdf"><a href="/node/32386/pdf" type="application/pdf" target="_blank">PDF Version</a></span>
</div>          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2024-07-02T12:33:00Z" timezone="America/New_York" class="datetime">Jul 2, 2024</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-announces-fda-acceptance-new-drug-application" hreflang="en">Vertex Announces FDA Acceptance of New Drug Application for Vanzacaftor/Tezacaftor/Deutivacaftor, a Next-In-Class Triple Combination Treatment for Cystic Fibrosis</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  - Vanza triple granted priority review with Prescription Drug User Fee Act (PDUFA) target action date of January 2, 2025 – - EU Marketing Authorization Application (MAA) submission also validated by European Medicines Agency (EMA) BOSTON --(BUSINESS WIRE)--Jul.
  </summary>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-announces-fda-acceptance-new-drug-application" target="_self">View HTML</a></span>
<div class="file-link pdf-file-link">
  <span class="file file--mime-application-pdf file--application-pdf"><a href="/node/32341/pdf" type="application/pdf" target="_blank">PDF Version</a></span>
</div>          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2024-07-01T20:05:00Z" timezone="America/New_York" class="datetime">Jul 1, 2024</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-announce-second-quarter-2024-financial-results-august-1" hreflang="en">Vertex to Announce Second Quarter 2024 Financial Results on August 1</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  BOSTON --(BUSINESS WIRE)--Jul. 1, 2024-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its second quarter 2024 financial results on Thursday, August 1, 2024 after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET .
  </summary>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-announce-second-quarter-2024-financial-results-august-1" target="_self">View HTML</a></span>
<div class="file-link pdf-file-link">
  <span class="file file--mime-application-pdf file--application-pdf"><a href="/node/32336/pdf" type="application/pdf" target="_blank">PDF Version</a></span>
</div>          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2024-06-21T19:45:00Z" timezone="America/New_York" class="datetime">Jun 21, 2024</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-announces-positive-results-ongoing-phase-12-study-vx-880" hreflang="en">Vertex Announces Positive Results From Ongoing Phase 1/2 Study of VX-880 for the Treatment of Type 1 Diabetes Presented at the American Diabetes Association 84th Scientific Sessions</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  – All 12 patients who received the full dose of VX-880 as a single infusion demonstrated islet cell engraftment and glucose-responsive insulin production by Day 90 – – All patients achieved ADA -recommended target HbA1c levels 70% time-in-range (70-180 mg/dL), and 11 of 12 patients
  </summary>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-announces-positive-results-ongoing-phase-12-study-vx-880" target="_self">View HTML</a></span>
<div class="file-link pdf-file-link">
  <span class="file file--mime-application-pdf file--application-pdf"><a href="/node/32311/pdf" type="application/pdf" target="_blank">PDF Version</a></span>
</div>          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2024-06-14T07:03:00Z" timezone="America/New_York" class="datetime">Jun 14, 2024</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-presents-positive-long-term-data-casgevytm-exagamglogene" hreflang="en">Vertex Presents Positive Long-Term Data On CASGEVY™ (exagamglogene autotemcel) at the 2024 Annual European Hematology Association (EHA) Congress</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  - Results from CLIMB-111, -121 and -131 accepted for oral presentation - - Data from these trials, with the longest follow-up of more than five years, demonstrate transformative, consistent and durable benefit of CASGEVY™ - - Safety profile consistent with busulfan conditioning and   autologous
  </summary>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-presents-positive-long-term-data-casgevytm-exagamglogene" target="_self">View HTML</a></span>
<div class="file-link pdf-file-link">
  <span class="file file--mime-application-pdf file--application-pdf"><a href="/node/32306/pdf" type="application/pdf" target="_blank">PDF Version</a></span>
</div>          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2024-06-07T16:00:00Z" timezone="America/New_York" class="datetime">Jun 7, 2024</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-presents-new-data-european-cystic-fibrosis-conference" hreflang="en">Vertex Presents New Data at the European Cystic Fibrosis Conference Demonstrating Significant Benefits of Treatment with TRIKAFTA®</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  - Results from a randomized, placebo-controlled study of TRIKAFTA ® in people with cystic fibrosis with rare, non- F508del CFTR mutations showed statistically significant and clinically meaningful improvements in the primary and all secondary endpoints - - Interim results of largest real-world
  </summary>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-presents-new-data-european-cystic-fibrosis-conference" target="_self">View HTML</a></span>
<div class="file-link pdf-file-link">
  <span class="file file--mime-application-pdf file--application-pdf"><a href="/node/32276/pdf" type="application/pdf" target="_blank">PDF Version</a></span>
</div>          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2024-05-22T20:05:00Z" timezone="America/New_York" class="datetime">May 22, 2024</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-participate-upcoming-june-investor-conferences" hreflang="en">Vertex to Participate in Upcoming June Investor Conferences</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  BOSTON --(BUSINESS WIRE)--May 22, 2024-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced management participation in two upcoming investor conferences. Dr. Reshma Kewalramani , Chief Executive Officer and President, will present at the William Blair 44 th Annual Growth Stock
  </summary>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-participate-upcoming-june-investor-conferences" target="_self">View HTML</a></span>
<div class="file-link pdf-file-link">
  <span class="file file--mime-application-pdf file--application-pdf"><a href="/node/32191/pdf" type="application/pdf" target="_blank">PDF Version</a></span>
</div>          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2024-05-15T14:30:00Z" timezone="America/New_York" class="datetime">May 15, 2024</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/jennifer-schneider-elected-vertex-board-directors" hreflang="en">Jennifer Schneider Elected to Vertex Board of Directors</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  BOSTON --(BUSINESS WIRE)--May 15, 2024-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Jennifer Schneider , M.D., M.S., has been elected to its Board of Directors as an independent director. Dr. Schneider has more than two decades of experience in the health care industry
  </summary>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/jennifer-schneider-elected-vertex-board-directors" target="_self">View HTML</a></span>
<div class="file-link pdf-file-link">
  <span class="file file--mime-application-pdf file--application-pdf"><a href="/node/32106/pdf" type="application/pdf" target="_blank">PDF Version</a></span>
</div>          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2024-05-06T20:01:00Z" timezone="America/New_York" class="datetime">May 6, 2024</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-reports-first-quarter-2024-financial-results" hreflang="en">Vertex Reports First Quarter 2024 Financial Results</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  — Product revenue of $2.69 billion , a 13% increase compared to Q1 2023; reiterated full year 2024 financial guidance, including product revenue guidance of $10.55 to $10.75 billion — — Submitted NDA and MAA filings for vanzacaftor triple in CF to FDA and EMA, respectively — — Initiated rolling NDA
  </summary>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-reports-first-quarter-2024-financial-results" target="_self">View HTML</a></span>
<div class="file-link pdf-file-link">
  <span class="file file--mime-application-pdf file--application-pdf"><a href="/node/32071/pdf" type="application/pdf" target="_blank">PDF Version</a></span>
</div>          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2024-04-26T15:43:00Z" timezone="America/New_York" class="datetime">Apr 26, 2024</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-announces-european-commission-approval-kalydecor-treat" hreflang="en">Vertex Announces European Commission Approval for KALYDECO® to Treat Infants With Cystic Fibrosis Ages 1 Month and Older</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  -   KALYDECO   ® is the first and only medicine approved in the EU in this age group to treat the underlying cause of cystic fibrosis for specific mutations in the CFTR gene - LONDON --(BUSINESS WIRE)--Apr. 26, 2024-- Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European
  </summary>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-announces-european-commission-approval-kalydecor-treat" target="_self">View HTML</a></span>
<div class="file-link pdf-file-link">
  <span class="file file--mime-application-pdf file--application-pdf"><a href="/node/32016/pdf" type="application/pdf" target="_blank">PDF Version</a></span>
</div>          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2024-04-23T04:45:00Z" timezone="America/New_York" class="datetime">Apr 23, 2024</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-and-treefrog-therapeutics-announce-licensing-agreement" hreflang="en">Vertex and TreeFrog Therapeutics Announce Licensing Agreement and Collaboration to Optimize Production of Vertex’s Cell Therapies for Type 1 Diabetes</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  Vertex obtains an exclusive license to&amp;nbsp;TreeFrog&#039;s C-Stem TM &amp;nbsp; manufacturing technology in type 1 diabetes&amp;nbsp; TreeFrog and Vertex to collaborate on scale-up of fully differentiated, insulin-producing pancreatic islet cells&amp;nbsp; BOSTON and BORDEAUX, France , April 23, 2024 /PRNewswire/ -- Vertex
  </summary>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-and-treefrog-therapeutics-announce-licensing-agreement" target="_self">View HTML</a></span>
<div class="file-link pdf-file-link">
  <span class="file file--mime-application-pdf file--application-pdf"><a href="/node/32011/pdf" type="application/pdf" target="_blank">PDF Version</a></span>
</div>          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2024-04-18T12:00:00Z" timezone="America/New_York" class="datetime">Apr 18, 2024</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-announces-advancements-suzetrigine-vx-548-acute-and" hreflang="en">Vertex Announces Advancements of Suzetrigine (VX-548) in Acute and Neuropathic Pain</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  – Rolling submission for suzetrigine moderate-to-severe acute pain NDA granted by FDA; first module submitted and on track to complete filing this quarter – – Successful completion of end-of-phase 2 FDA meeting for pain associated with diabetic peripheral neuropathy (DPN); Phase 3 program to
  </summary>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-announces-advancements-suzetrigine-vx-548-acute-and" target="_self">View HTML</a></span>
<div class="file-link pdf-file-link">
  <span class="file file--mime-application-pdf file--application-pdf"><a href="/node/31996/pdf" type="application/pdf" target="_blank">PDF Version</a></span>
</div>          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2024-04-10T20:01:00Z" timezone="America/New_York" class="datetime">Apr 10, 2024</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-enters-agreement-acquire-alpine-immune-sciences" hreflang="en">Vertex Enters Into Agreement to Acquire Alpine Immune Sciences</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  - Alpine is a clinical stage biotechnology company focused on discovering and developing innovative, protein-based immunotherapies - - Alpine’s lead product, povetacicept, demonstrated best-in-class potential in patients with IgA nephropathy (IgAN); Phase 3 to initiate in H2 2024 - - Povetacicept
  </summary>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-enters-agreement-acquire-alpine-immune-sciences" target="_self">View HTML</a></span>
<div class="file-link pdf-file-link">
  <span class="file file--mime-application-pdf file--application-pdf"><a href="/node/31956/pdf" type="application/pdf" target="_blank">PDF Version</a></span>
</div>          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2024-04-09T20:05:00Z" timezone="America/New_York" class="datetime">Apr 9, 2024</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-announce-first-quarter-2024-financial-results-may-6" hreflang="en">Vertex to Announce First Quarter 2024 Financial Results on May 6</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  BOSTON --(BUSINESS WIRE)--Apr. 9, 2024-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its first quarter 2024 financial results on Monday, May 6, 2024 after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET .
  </summary>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-announce-first-quarter-2024-financial-results-may-6" target="_self">View HTML</a></span>
<div class="file-link pdf-file-link">
  <span class="file file--mime-application-pdf file--application-pdf"><a href="/node/31931/pdf" type="application/pdf" target="_blank">PDF Version</a></span>
</div>          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2024-04-01T12:00:00Z" timezone="America/New_York" class="datetime">Apr 1, 2024</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-advances-inaxaplin-vx-147-phase-3-portion-adaptive-phase" hreflang="en">Vertex Advances Inaxaplin (VX-147) into Phase 3 Portion of Adaptive Phase 2/3 Clinical Trial for the Treatment of APOL1-Mediated Kidney Disease</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  – 45 mg once daily oral dose selected for Phase 3 – – Results support trial expansion to lower age group and study will now include adolescents ages 10-17 years – – If positive, pre-planned interim analysis at Week 48 may serve as the basis for accelerated approval in the U.S.
  </summary>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-advances-inaxaplin-vx-147-phase-3-portion-adaptive-phase" target="_self">View HTML</a></span>
<div class="file-link pdf-file-link">
  <span class="file file--mime-application-pdf file--application-pdf"><a href="/node/31906/pdf" type="application/pdf" target="_blank">PDF Version</a></span>
</div>          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2024-03-21T12:00:00Z" timezone="America/New_York" class="datetime">Mar 21, 2024</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-announces-fda-clearance-investigational-new-drug-0" hreflang="en">Vertex Announces FDA Clearance of Investigational New Drug Application for VX-407 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  – ADPKD is the most common inherited kidney disease, with no treatments currently available that address the underlying cause of disease – – Vertex to initiate a Phase 1 clinical trial in healthy volunteers this month – – ADPKD is Vertex’s 10th disease area in the clinic, further expanding the
  </summary>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-announces-fda-clearance-investigational-new-drug-0" target="_self">View HTML</a></span>
<div class="file-link pdf-file-link">
  <span class="file file--mime-application-pdf file--application-pdf"><a href="/node/31901/pdf" type="application/pdf" target="_blank">PDF Version</a></span>
</div>          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2024-02-23T12:10:00Z" timezone="America/New_York" class="datetime">Feb 23, 2024</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-receives-chmp-positive-opinion-kalydecor-treatment" hreflang="en">Vertex Receives CHMP Positive Opinion for KALYDECO® for the Treatment of Infants With Cystic Fibrosis Ages 1 Month and Older</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  - If approved, KALYDECO ® will be the first and only medicine approved in Europe to treat the underlying cause of cystic fibrosis in babies as young as 1 month with specific mutations in the CFTR gene - LONDON --(BUSINESS WIRE)--Feb. 23, 2024-- Vertex Pharmaceuticals (Nasdaq: VRTX) today announced
  </summary>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-receives-chmp-positive-opinion-kalydecor-treatment" target="_self">View HTML</a></span>
<div class="file-link pdf-file-link">
  <span class="file file--mime-application-pdf file--application-pdf"><a href="/node/31796/pdf" type="application/pdf" target="_blank">PDF Version</a></span>
</div>          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2024-02-20T21:05:00Z" timezone="America/New_York" class="datetime">Feb 20, 2024</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-participate-upcoming-investor-conferences-0" hreflang="en">Vertex to Participate in Upcoming Investor Conferences</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  BOSTON --(BUSINESS WIRE)--Feb. 20, 2024-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Charles Wagner , Executive Vice President and Chief Financial Officer, and David Altshuler , M.D., Ph.D., Executive Vice President, Global Research , and Chief Scientific Officer, will
  </summary>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-participate-upcoming-investor-conferences-0" target="_self">View HTML</a></span>
<div class="file-link pdf-file-link">
  <span class="file file--mime-application-pdf file--application-pdf"><a href="/node/31716/pdf" type="application/pdf" target="_blank">PDF Version</a></span>
</div>          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2024-02-13T06:59:00Z" timezone="America/New_York" class="datetime">Feb 13, 2024</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/european-commission-approves-first-crisprcas9-gene-edited" hreflang="en">European Commission Approves First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemcel), for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  - Over 8,000 patients 12 years of age and older with severe sickle cell disease or transfusion-dependent beta thalassemia may be eligible for treatment - LONDON --(BUSINESS WIRE)--Feb. 13, 2024-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that the European Commission has
  </summary>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/european-commission-approves-first-crisprcas9-gene-edited" target="_self">View HTML</a></span>
<div class="file-link pdf-file-link">
  <span class="file file--mime-application-pdf file--application-pdf"><a href="/node/31576/pdf" type="application/pdf" target="_blank">PDF Version</a></span>
</div>          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2024-02-05T21:06:00Z" timezone="America/New_York" class="datetime">Feb 5, 2024</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-reports-fourth-quarter-and-full-year-2023-financial" hreflang="en">Vertex Reports Fourth Quarter and Full Year 2023 Financial Results</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  — Full year product revenue of $9.87 billion , an 11% increase compared to full year 2022 — — Company provides full year 2024 product revenue guidance of $10.55 to $10.75 billion — — CASGEVY TM approved in the U.S. , Great Britain , the Kingdom of Saudi Arabia and Bahrain — — Vertex on track to
  </summary>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-reports-fourth-quarter-and-full-year-2023-financial" target="_self">View HTML</a></span>
<div class="file-link pdf-file-link">
  <span class="file file--mime-application-pdf file--application-pdf"><a href="/node/31456/pdf" type="application/pdf" target="_blank">PDF Version</a></span>
</div>          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2024-02-05T21:01:00Z" timezone="America/New_York" class="datetime">Feb 5, 2024</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-announces-positive-results-pivotal-trials" hreflang="en">Vertex Announces Positive Results From Pivotal Trials of Vanzacaftor/Tezacaftor/Deutivacaftor, Next-In-Class Triple Combination Treatment for Cystic Fibrosis</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  – Treatment with the once-daily vanza triple CFTR modulator regimen met all primary and key secondary endpoints in two randomized controlled trials in people with CF ages 12 years and older – – Results were more pronounced in the single-arm study in children ages 6 to 11 years, demonstrating the
  </summary>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-announces-positive-results-pivotal-trials" target="_self">View HTML</a></span>
<div class="file-link pdf-file-link">
  <span class="file file--mime-application-pdf file--application-pdf"><a href="/node/31451/pdf" type="application/pdf" target="_blank">PDF Version</a></span>
</div>          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2024-01-30T11:28:00Z" timezone="America/New_York" class="datetime">Jan 30, 2024</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-announces-positive-results-vx-548-phase-3-program" hreflang="en">Vertex Announces Positive Results From the VX-548 Phase 3 Program for the Treatment of Moderate-to-Severe Acute Pain</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  – Treatment with VX-548 led to statistically significant improvement in pain compared to placebo as well as a clinically meaningful reduction in pain from baseline in both the abdominoplasty and bunionectomy randomized controlled trials – – Treatment with VX-548 was also shown to be effective in
  </summary>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-announces-positive-results-vx-548-phase-3-program" target="_self">View HTML</a></span>
<article class="node node--nir-asset--asset-link node--type-nir-asset node--view-mode-asset-link">
  <div class="node__content">
    
      <div class="field field--name-field-nir-document field--type-file field--label-hidden field__items">
              <div class="field__item">
            <div class="file-link">
  <span class="file file--mime-application-pdf file--application-pdf"> <a href="/static-files/77763a96-8aa2-4dad-89b3-d5e3f1513ed6" type="application/pdf" title="1.30.24_VX-548 Phase 3 Acute Results_FINAL.pdf">PDF Version</a></span><span class="filesize"> 292.8 KB</span>
</div>

        </div>
          </div>
  
  </div>
</article>
          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2024-01-17T13:00:00Z" timezone="America/New_York" class="datetime">Jan 17, 2024</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-announce-fourth-quarter-and-full-year-2023-financial" hreflang="en">Vertex to Announce Fourth Quarter and Full Year 2023 Financial Results on February 5</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  BOSTON --(BUSINESS WIRE)--Jan. 17, 2024-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its fourth quarter and full year 2023 financial results on Monday, February 5, 2024 after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET .
  </summary>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-announce-fourth-quarter-and-full-year-2023-financial" target="_self">View HTML</a></span>
<div class="file-link pdf-file-link">
  <span class="file file--mime-application-pdf file--application-pdf"><a href="/node/31406/pdf" type="application/pdf" target="_blank">PDF Version</a></span>
</div>          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2024-01-16T19:24:00Z" timezone="America/New_York" class="datetime">Jan 16, 2024</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-announces-us-fda-approval-casgevytm-exagamglogene" hreflang="en">Vertex Announces US FDA Approval of CASGEVY™ (exagamglogene autotemcel) for the Treatment of Transfusion-Dependent Beta Thalassemia</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  - Approximately 1,000 patients in the U.S. 12 years of age and older are now eligible for this one-time treatment - BOSTON --(BUSINESS WIRE)--Jan. 16, 2024-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that the U.S. Food and Drug Administration (FDA) has approved CASGEVY™
  </summary>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-announces-us-fda-approval-casgevytm-exagamglogene" target="_self">View HTML</a></span>
<div class="file-link pdf-file-link">
  <span class="file file--mime-application-pdf file--application-pdf"><a href="/node/31401/pdf" type="application/pdf" target="_blank">PDF Version</a></span>
</div>          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2024-01-09T17:42:00Z" timezone="America/New_York" class="datetime">Jan 9, 2024</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-announces-approval-first-crisprcas9-gene-edited-therapy" hreflang="en">Vertex Announces Approval of First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™, for the Treatment of Sickle Cell Disease (SCD) and Transfusion-Dependent Beta Thalassemia (TDT) in Kingdom of Saudi Arabia</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  - CASGEVY™ is first medicine ever to be evaluated through the SFDA’s Breakthrough Medicines Program - - First treatment center in Saudi Arabia has been activated - BOSTON --(BUSINESS WIRE)--Jan. 9, 2024-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that the Saudi Food and
  </summary>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-announces-approval-first-crisprcas9-gene-edited-therapy" target="_self">View HTML</a></span>
<div class="file-link pdf-file-link">
  <span class="file file--mime-application-pdf file--application-pdf"><a href="/node/31381/pdf" type="application/pdf" target="_blank">PDF Version</a></span>
</div>          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2024-01-07T20:00:00Z" timezone="America/New_York" class="datetime">Jan 7, 2024</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-provides-pipeline-and-business-updates-advance-upcoming" hreflang="en">Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  BOSTON --(BUSINESS WIRE)--Jan. 7, 2024-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced multiple program updates ahead of upcoming investor meetings in January, including the company’s scheduled webcast from the 42 nd Annual J.P. Morgan Healthcare Conference on Monday, January
  </summary>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-provides-pipeline-and-business-updates-advance-upcoming" target="_self">View HTML</a></span>
<div class="file-link pdf-file-link">
  <span class="file file--mime-application-pdf file--application-pdf"><a href="/node/31366/pdf" type="application/pdf" target="_blank">PDF Version</a></span>
</div>          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2023-12-18T21:05:00Z" timezone="America/New_York" class="datetime">Dec 18, 2023</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-present-42nd-annual-jp-morgan-healthcare-conference" hreflang="en">Vertex to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 8</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  BOSTON --(BUSINESS WIRE)--Dec. 18, 2023-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Dr. Reshma Kewalramani , Chief Executive Officer and President, will present at the 42 nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2024 at 11:15 a.m.
  </summary>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-present-42nd-annual-jp-morgan-healthcare-conference" target="_self">View HTML</a></span>
<div class="file-link pdf-file-link">
  <span class="file file--mime-application-pdf file--application-pdf"><a href="/node/31341/pdf" type="application/pdf" target="_blank">PDF Version</a></span>
</div>          </td>
              </tr>
      </tbody>
</table>

    </div>
  
        <nav class="pager" role="navigation" aria-labelledby="pagination-heading">
    <h4 id="pagination-heading" class="visually-hidden">Pagination</h4>
    <ul class="pager__items js-pager__items">
                                                        <li class="pager__item is-active">
                                          <a href="?items_per_page_toggle=1&amp;page=0" title="Current page" aria-current="page">
            <span class="visually-hidden">
              Current page
            </span>1</a>
        </li>
              <li class="pager__item">
                                          <a href="?items_per_page_toggle=1&amp;page=1" title="Go to page 2">
            <span class="visually-hidden">
              Page
            </span>2</a>
        </li>
              <li class="pager__item">
                                          <a href="?items_per_page_toggle=1&amp;page=2" title="Go to page 3">
            <span class="visually-hidden">
              Page
            </span>3</a>
        </li>
              <li class="pager__item">
                                          <a href="?items_per_page_toggle=1&amp;page=3" title="Go to page 4">
            <span class="visually-hidden">
              Page
            </span>4</a>
        </li>
                          <li class="pager__item pager__item--ellipsis" role="presentation" aria-hidden="true">&hellip;</li>
                          <li class="pager__item pager__item--next">
          <a href="?items_per_page_toggle=1&amp;page=1" title="Go to next page" rel="next">
            <span class="visually-hidden">Next page</span>
            <span aria-hidden="true">Next</span>
          </a>
        </li>
                          <li class="pager__item pager__item--last">
          <a href="?items_per_page_toggle=1&amp;page=16" title="Go to last page">
            <span class="visually-hidden">Last page</span>
            <span aria-hidden="true">Last</span>
          </a>
        </li>
          </ul>
  </nav>

  
          <div class="view-footer">
          <div class="results-summary">Displaying 1 - 50 of 836 results</div>
        </div>
    </div>
</div>

  </div>
</div>
        </div>
      </div>
    </div>
  </div>

</div><!-- /.boxton -->

  </div>
</article>

  </div>

  </div>

                </div>
            

            


            <footer>
                                <div class="column footer-sitemap">
                    <div class="row small-up-1 medium-up-4 large-up-4 flexy">
                        

<div role="navigation" aria-labelledby="block-footercol1-menu" id="block-footercol1" class="block--system-menu-blockfooter-col-1 block--system-menu-blockfooter-col-1--5816 block--footer-first--system-menu-block--footer-col-1 block--footer-first--system-menu-block--footer-col-1--5816 block--da449755-c1be-4e93-bf75-4db21af16447 block--da449755-c1be-4e93-bf75-4db21af16447--5816 block block-menu navigation block-system-menublock menu--footer-col-1 small-6 large-3 columns">
                        
    <p class="visually-hidden" id="block-footercol1-menu" class="lead">Footer Col 1</p>
    

                              <ul data-block-uuid="da449755-c1be-4e93-bf75-4db21af16447" class="menu vertical">
                                                                        <li class="notSocialLink side-menu__item">
                          <a href="/press-releases" target="" rel="" data-drupal-link-system-path="node/5816" class="is-active" aria-current="page">News &amp; Events</a>
                              </li>
                                                                    <li class="notSocialLink side-menu__item">
                          <a href="/stock-information" target="" rel="" data-drupal-link-system-path="node/5916">Stock Information</a>
                              </li>
                                                                    <li class="notSocialLink side-menu__item">
                          <a href="/stock-information/analyst-coverage" target="" rel="" data-drupal-link-system-path="node/5896">Analyst Coverage</a>
                              </li>
          </ul>
  


    </div>


<div role="navigation" aria-labelledby="block-footercol2-menu" id="block-footercol2" class="block--system-menu-blockfooter-col-2 block--system-menu-blockfooter-col-2--31451 block--footer-first--system-menu-block--footer-col-2 block--footer-first--system-menu-block--footer-col-2--31451 block--bdf059f5-091d-492a-8531-746af0f478ff block--bdf059f5-091d-492a-8531-746af0f478ff--31451 block block-menu navigation block-system-menublock menu--footer-col-2 small-6 large-3 columns">
                        
    <p class="visually-hidden" id="block-footercol2-menu" class="lead">Footer Col 2</p>
    

                              <ul data-block-uuid="bdf059f5-091d-492a-8531-746af0f478ff" class="menu vertical">
                                                                        <li class="notSocialLink side-menu__item">
                          <a href="/financial-information/quarterly-results" target="" rel="" data-drupal-link-system-path="node/5986">Financial Information</a>
                              </li>
                                                                    <li class="notSocialLink side-menu__item">
                          <a href="/corporate-governances" target="" rel="" data-drupal-link-system-path="node/24511">Corporate Governance</a>
                              </li>
                                                                    <li class="notSocialLink side-menu__item">
                          <a href="/contact-us" target="" rel="" data-drupal-link-system-path="node/5981">Investor Resources</a>
                              </li>
          </ul>
  


    </div>


<div role="navigation" aria-labelledby="block-footercol3-menu" id="block-footercol3" class="block--system-menu-blockfooter-col-3 block--system-menu-blockfooter-col-3--31451 block--footer-first--system-menu-block--footer-col-3 block--footer-first--system-menu-block--footer-col-3--31451 block--7e76016d-878b-43d2-a4f3-4289a342a22d block--7e76016d-878b-43d2-a4f3-4289a342a22d--31451 block block-menu navigation block-system-menublock menu--footer-col-3 small-6 large-3 columns">
            
    <p id="block-footercol3-menu" class="lead">Vertex Websites</p>
    

                              <ul data-block-uuid="7e76016d-878b-43d2-a4f3-4289a342a22d" class="menu vertical">
                                                                        <li class="notSocialLink side-menu__item">
                          <a href="https://www.vrtx.com/">Global</a>
                              </li>
                                                                    <li class="notSocialLink side-menu__item">
                          <a href="https://www.vrtx.fr/">France</a>
                              </li>
                                                                    <li class="notSocialLink side-menu__item">
                          <a href="https://www.vrtx.de/">Germany</a>
                              </li>
                                                                    <li class="notSocialLink side-menu__item">
                          <a href="https://www.vrtx.ca/">Canada</a>
                              </li>
                                                                    <li class="notSocialLink side-menu__item">
                          <a href="https://www.vrtxpharma.co.uk/">United Kingdom</a>
                              </li>
                                                                    <li class="notSocialLink side-menu__item">
                          <a href="https://www.vrtx.com/en-us">United States</a>
                              </li>
          </ul>
  


    </div>


<div role="navigation" aria-labelledby="block-socialmedia-menu" id="block-socialmedia" class="block--system-menu-blocksocial-media block--system-menu-blocksocial-media--31451 block--footer-first--system-menu-block--social-media block--footer-first--system-menu-block--social-media--31451 block--5d1642a9-9f5b-4bed-9f56-6157a76875d1 block--5d1642a9-9f5b-4bed-9f56-6157a76875d1--31451 block block-menu navigation block-system-menublock menu--social-media small-6 large-3 columns">
                        
    <p class="visually-hidden" id="block-socialmedia-menu" class="lead">Social Media</p>
    

                              <ul data-block-uuid="5d1642a9-9f5b-4bed-9f56-6157a76875d1" class="menu vertical">
                                                                                              <li class="isSocialLink side-menu__item">
                            <a href="https://www.facebook.com/VertexPharmaInc" class="facebook" aria-label="facebook">
                  <span class="fa-stack"><i class="fa fa-circle fa-stack-2x"></i><i class="fa fa-facebook fa-stack-1x fa-inverse"></i></span>
                </a>
                              </li>
                                                                                          <li class="isSocialLink side-menu__item">
                            <a href="https://www.linkedin.com/company/vertex-pharmaceuticals" class="linkedin" aria-label="linkedin">
                  <span class="fa-stack"><i class="fa fa-circle fa-stack-2x"></i><i class="fa fa-linkedin fa-stack-1x fa-inverse"></i></span>
                </a>
                              </li>
                                                                                          <li class="isSocialLink side-menu__item">
                            <a href="https://twitter.com/VertexPharma" class="x-twitter" aria-label="x-twitter">
                  <span class="fa-stack"><i class="fa fa-circle fa-stack-2x"></i><i class="fa fa-x-twitter fa-stack-1x fa-inverse"></i></span>
                </a>
                              </li>
                                                                                          <li class="isSocialLink side-menu__item">
                            <a href="https://www.youtube.com/channel/UCrNu_QIE9exwVQnWKgr1toQ/featured" class="youtube" aria-label="youtube">
                  <span class="fa-stack"><i class="fa fa-circle fa-stack-2x"></i><i class="fa fa-youtube fa-stack-1x fa-inverse"></i></span>
                </a>
                              </li>
          </ul>
  


    </div>

                    </div>
                </div>
                                <div class="column primary footer-global">
                    <div class="row">
                                                <div class="medium-6 columns">
                                                        <div class="region region-footer">
                                <nav role="navigation" aria-labelledby="block-footerbottom-menu" class="block--system-menu-blockfooter-bottom block--system-menu-blockfooter-bottom--5986 block--footer--system-menu-block--footer-bottom block--footer--system-menu-block--footer-bottom--5986 block--e172c75d-9834-4259-9057-aa69edfb5161 block--e172c75d-9834-4259-9057-aa69edfb5161--5986 block block-menu navigation block-system-menublock menu--footer-bottom">
                                    <ul data-block-uuid="e172c75d-9834-4259-9057-aa69edfb5161" class="menu side-menu">
                                        <li class="side-menu__item">
                                            <a href="https://www.vrtx.com/international-privacy" target="_blank">Privacy Policy</a>
                                        </li>
                                        <li class="side-menu__item">
                                            <a href="https://www.vrtx.com/terms-and-conditions" target="_blank">Terms of Use</a>
                                        </li>
                                        <li class="side-menu__item">
                                            <!-- OneTrust Cookies Settings button start -->
                                            <a id="ot-sdk-btn" class="ot-sdk-show-settings">Your Privacy Choices</a>
                                            <!-- OneTrust Cookies Settings button end -->
                                        </li>
                                        <li>
                                            <img src="/sites/g/files/knoqqb74911/themes/site/nir_pid2172/dist/images/privacyoptions.svg" style="width:25px">
                                        </li>
                                    </ul>
                                </nav>
                            </div>
                        </div>
                        
                        <div class="medium-6 columns">
                            <ul class="menu float-right">
                                <li class="menu-text">Copyright &copy; 2025</li>
                            </ul>
                        </div>
                    </div>
                </div>
            </footer>


        </div> <!-- /off-canvas-content -->

        <div class="js-off-canvas-exit"></div>


    </div> <!-- /off-canvas-wrapper-inner -->
</div> <!-- /off-canvas-wrapper -->
  </div>

    
        <script type="application/json" data-drupal-selector="drupal-settings-json">{"path":{"baseUrl":"\/","pathPrefix":"","currentPath":"node\/5816","currentPathIsAdmin":false,"isFront":false,"currentLanguage":"en"},"pluralDelimiter":"\u0003","suppressDeprecationErrors":true,"ajaxPageState":{"libraries":"eJyVUlFuwzAIvVAUa_3ZAXaCaQewiI06VhsqIG1z-zpOpa1TN22yhB_P8IzBTBonMAzcACVhG_gr5SJlAu1kOmAmF40ZvK2poIVP2EMq6AG9B8SpSDoEYCiLeVRw4n0TbjrvoP6ncItd-4fYisBRMUmtyI0n4V-1H7Ljmg6c_5Vj3uzrLH4rbS5OtTUHwr3bT4-w33q5ghE-4BIh55gKmEUoqL717kh59_S8C3JCVcqbdL9pe1X45m9VvKzwzZfS2tUzzjgZOUYWp9Qm9IAbb_ugkOkSCywyu4U7b7A2Bqxh_QnDifBsoduxSp4LXgFrIOEu","theme":"nir_pid2172","theme_token":null},"ajaxTrustedUrl":[],"nir_admin_use_chosen":true,"nir_admin_use_select2":false,"user":{"uid":0,"permissionsHash":"45e7a25462df2b241c7eec49f3c8a237acab787c5b520da38b10415af90811be"}}</script>
<script src="/sites/g/files/knoqqb74911/themes/site/nir_pid2172/dist/js/jquery-2.1.4.min.js?ssxojg"></script>
<script src="/sites/g/files/knoqqb74911/themes/site/nir_pid2172/dist/js/jquery.circliful.js?ssxojg"></script>
<script src="/sites/g/files/knoqqb74911/themes/site/nir_pid2172/dist/js/theme-embedded.js?ssxojg"></script>
<script src="/sites/g/files/knoqqb74911/themes/site/nir_pid2172/dist/js/ndq-functions.js?ssxojg"></script>
<script src="/sites/g/files/knoqqb74911/themes/site/nir_pid2172/dist/js/foundation.min.js?ssxojg"></script>
<script src="/sites/g/files/knoqqb74911/themes/site/nir_pid2172/dist/js/vivus.min.js?ssxojg"></script>
<script src="/sites/g/files/knoqqb74911/themes/site/nir_pid2172/dist/js/theme-embedded-2.js?ssxojg"></script>
<script src="/sites/g/files/knoqqb74911/themes/site/nir_pid2172/js/modal-video.js?ssxojg"></script>
<script src="/sites/g/files/knoqqb74911/themes/site/nir_pid2172/js/modal-video.run.js?ssxojg"></script>
<script src="/sites/g/files/knoqqb74911/files/js/js_yoTi3ajw4iS9VMtHeeJMhx7zxXd9S5AacrChSDHVlFQ.js?scope=footer&amp;delta=9&amp;language=en&amp;theme=nir_pid2172&amp;include=eJyVj0sOwjAMRC-EEtENB-AEiANETmIV0zSuEpfP7UldJATqBmXh8ctY9mQqLgwYSbi4CNKeT1jtR-5ys4xzEhqbDex3q78eKioX5uShKJwodvtDZ_mGpVBEhXf0lQRdZqHQ1mww867qr8JhcOECRexPb1QfF3mWZ6Lcr5dCGVA0ivOpOewmNYHHEXL8a0Y3nmaWNcwE_Rp7EQau8HAQowsJanWQsEh9AVtyirg"></script>
<script src="/core/assets/vendor/ckeditor5/ckeditor5-dll/ckeditor5-dll.js?v=41.3.1"></script>
<script src="/profiles/nasdaqir/modules/custom/nir_ckeditor_datatables/js/build/datatables.js?v=1.10.9"></script>
<script src="/sites/g/files/knoqqb74911/files/js/js_GZWqVv5lmgvMD-78CCnz6GUVTpAe1Qj92_PpS3CTNZA.js?scope=footer&amp;delta=12&amp;language=en&amp;theme=nir_pid2172&amp;include=eJyVj0sOwjAMRC-EEtENB-AEiANETmIV0zSuEpfP7UldJATqBmXh8ctY9mQqLgwYSbi4CNKeT1jtR-5ys4xzEhqbDex3q78eKioX5uShKJwodvtDZ_mGpVBEhXf0lQRdZqHQ1mww867qr8JhcOECRexPb1QfF3mWZ6Lcr5dCGVA0ivOpOewmNYHHEXL8a0Y3nmaWNcwE_Rp7EQau8HAQowsJanWQsEh9AVtyirg"></script>

    <!-- Adobe Omniture JS Rewrite -->
<script type="text/plain" class="optanon-category-C0004">var s_CCSWebHostingAccount = "trcgvertex";</script>
<script src="//assets.adobedtm.com/898335afd880/c52ee8aa1e90/launch-5ef258dce664.min.js" type="text/plain" class="optanon-category-C0004"></script>
  </body>
</html>
